| Changing R&D models in research-based pharmaceutical companies A Schuhmacher, O Gassmann, M Hinder Journal of translational medicine 14, 1-11, 2016 | 395 | 2016 |
| Models for open innovation in the pharmaceutical industry A Schuhmacher, PG Germann, H Trill, O Gassmann Drug discovery today 18 (23-24), 1133-1137, 2013 | 202 | 2013 |
| Translational precision medicine: an industry perspective D Hartl, V de Luca, A Kostikova, J Laramie, S Kennedy, E Ferrero, ... Journal of translational medicine 19 (1), 245, 2021 | 95 | 2021 |
| Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? A Schuhmacher, O Gassmann, N McCracken, M Hinder Journal of translational medicine 16, 1-14, 2018 | 82 | 2018 |
| The upside of being a digital pharma player A Schuhmacher, A Gatto, M Hinder, M Kuss, O Gassmann Drug discovery today 25 (9), 1569-1574, 2020 | 56 | 2020 |
| Identification and characterization of secreted effector proteins of Chlamydophila pneumoniae TW183 M Herrmann, A Schuhmacher, I Mühldorfer, K Melchers, C Prothmann, ... Research in microbiology 157 (6), 513-524, 2006 | 49 | 2006 |
| R&D efficiency of leading pharmaceutical companies–A 20-year analysis A Schuhmacher, L Wilisch, M Kuss, A Kandelbauer, M Hinder, ... Drug discovery today 26 (8), 1784-1789, 2021 | 48 | 2021 |
| Properties and function of the P type ion pumps cloned from Helicobacter pylori. K Melchers, L Herrmann, F Mauch, D Bayle, D Heuermann, ... Acta physiologica scandinavica. Supplementum 643, 123-135, 1998 | 47 | 1998 |
| Membrane topology of CadA homologous P-type ATPase of Helicobacter pylori as determined by expression of phoA fusions in Escherichia coli and the positive inside rule K Melchers, A Schuhmacher, A Buhmann, T Weitzenegger, D Belin, ... Research in microbiology 150 (8), 507-520, 1999 | 34 | 1999 |
| Open innovation: A paradigm shift in pharma R&D? A Schuhmacher, O Gassmann, D Bieniok, M Hinder, D Hartl Drug Discovery Today 27 (9), 2395-2405, 2022 | 28 | 2022 |
| Value creation in the pharmaceutical industry: the critical path to innovation A Schuhmacher, M Hinder, O Gassmann John Wiley & Sons, 2016 | 26 | 2016 |
| Big Techs and startups in pharmaceutical R&D–A 2020 perspective on artificial intelligence A Schuhmacher, A Gatto, M Kuss, O Gassmann, M Hinder Drug Discovery Today 26 (10), 2226-2231, 2021 | 24 | 2021 |
| Analysis of pharma R&D productivity–a new perspective needed A Schuhmacher, M Hinder, AS und Stein, D Hartl, O Gassmann Drug Discovery Today, 103726, 2023 | 22 | 2023 |
| Leading pharmaceutical innovation: How to win the life science race O Gassmann, A Schuhmacher, M Von Zedtwitz, G Reepmeyer Springer, 2018 | 22 | 2018 |
| Pre-clinical evaluation of advanced nerve guide conduits using a novel 3D in vitro testing model M Behbehani, A Glen, CS Taylor, A Schuhmacher, F Claeyssens, ... International journal of bioprinting 4 (1), 2018 | 19 | 2018 |
| How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective PG Germann, A Schuhmacher, J Harrison, R Law, K Haug, G Wong Human genomics 7, 1-6, 2013 | 16 | 2013 |
| The art of virtualizing pharma R&D A Schuhmacher, O Gassmann, M Kuss, M Hinder Drug Discovery Today 24, 2105-2107, 2019 | 15 | 2019 |
| A review of the pharmaceutical R&D efficiency: costs, timelines, and probabilities A Schuhmacher, O Gassmann, M Hinder Value creation in the pharmaceutical industry: the critical path to …, 2016 | 15 | 2016 |
| The significance of blockbusters in the pharmaceutical industry. A Schuhmacher, M Hinder, N Boger, D Hartl, O Gassmann drugs 62, 37, 2022 | 13 | 2022 |
| Systematic risk identification and assessment using a new risk map in pharmaceutical R&D A Schuhmacher, C Brieke, O Gassmann, M Hinder, D Hartl Drug discovery today 26 (12), 2786-2793, 2021 | 13 | 2021 |
Oliver GassmannUniversity of St.Gallen在 unisg.ch 的电子邮件经过验证
Oliver GassmannUniversity of St.Gallen在 unisg.ch 的电子邮件经过验证
Jörg GoldhahnETH Zurich在 ethz.ch 的电子邮件经过验证